Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Type 2 diabetes
FollowWhat is new in Type 2 diabetes research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- AD-233APhase 3 · NCT07816198
- AD-233A PlaceboPhase 3 · NCT07816198
- AD-233BPhase 3 · NCT07816198
- AD-233B PlaceboPhase 3 · NCT07816198
- AD-233CPhase 3 · NCT07816198
- AD-233DPhase 3 · NCT07816198
- aleniglipronPhase 3 · NCT07654374
- AlogliptinPhase 3 · NCT07093476
- ASC30 tablets A1Phase 3 · NCT07743450
- AspirinPhase 3 · NCT05633810
- Aspirin PlaceboPhase 3 · NCT05633810
- AT-001Phase 3 · NCT04083339
- AutoinjectorPhase 3 · NCT07871409
- BERLIM 25/20 ASSOCIATIONPhase 3 · NCT04602754
- BGM0504Phase 3 · NCT07064486 · NCT07743983
- BofanglutidePhase 3 · NCT07628985
- BR1019APhase 3 · NCT06220773
- BR1019A-1Phase 3 · NCT06220773
- BR1019BPhase 3 · NCT06220773
- BR1019B-1Phase 3 · NCT06220773
- BR1019CPhase 3 · NCT06220773
- BR1019C-1Phase 3 · NCT06220773
- CagrilintidePhase 3 · NCT07220759
- CagriSemaPhase 3 · NCT07817251 · NCT07564414
- CagriSema (Cagrilintide B and Semaglutide I)Phase 3 · NCT07282613
- Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solutionPhase 3 · NCT06192693
- Capsulized placebo transfer containing dilution solutionPhase 3 · NCT06192693
- Cilostazol / Ginko Leaf Dried Ext.Phase 3 · NCT06989697
- CMG190303(Dapagliflozin/Rosuvastatin)Phase 3 · NCT06772168
- ColchicinePhase 3 · NCT05633810
- Colchicine PlaceboPhase 3 · NCT05633810
- Comparator 1: Dapagliflozin/Rosuvastatin placeboPhase 3 · NCT06772168
- Control group 1Phase 3 · NCT07552389
- Control group 2Phase 3 · NCT07552389
- DA5221-B1Phase 3 · NCT06290349
- DA5221-B2Phase 3 · NCT06290349
- DA5221-T1Phase 3 · NCT06290349
- DA5221-T2Phase 3 · NCT06290349
- DapagliflozinPhase 3 · NCT05345327 · NCT05886088 · NCT07662044 · NCT07662109
- Dapagliflozin (DAPA)Phase 3 · NCT07082114 · NCT07020377 · NCT06820567
- Dapagliflozin +Finerenone armPhase 3 · NCT07598864
- Dapagliflozin armPhase 3 · NCT07598864
- Dapagliflozin-matched placeboPhase 3 · NCT07662044 · NCT07662109
- DIAB-PHC1Phase 3 · NCT07279909
- DorzagliatinPhase 3 · NCT05098470
- Drug: : 10 mg BGM0504 Administered SCPhase 3 · NCT06716203
- Drug: 5 mg BGM0504 Administered SCPhase 3 · NCT06716203 · NCT06716216
- Drug: Placebo Administered SCPhase 3 · NCT06716203
- Drug: Semaglutide Administered SCPhase 3 · NCT06716216
- Drug:10 mg BGM0504 Administered SCPhase 3 · NCT06716216
- DulaglutidePhase 3 · NCT06257966 · NCT06739122 · NCT07668336 · NCT07677891
- Dulaglutide InjectionPhase 3 · NCT07156539
- Duodenojejunal bypassPhase 3 · NCT05211375
- DWC202518Phase 3 · NCT07619833
- DWP16001Phase 3 · NCT07619833
- Efsubaglutide Alfa 1mg QW and 3mg Q2WPhase 3 · NCT06900075
- Efsubaglutide Alfa 3mg Q2W and 1mg QWPhase 3 · NCT06900075
- ElecoglipronPhase 3 · NCT07664553 · NCT07662213 · NCT07662135 · NCT07667803 · NCT07775404 · NCT07662044 · NCT07534592 · NCT07662109
- Elecoglipron-matched placeboPhase 3 · NCT07662044 · NCT07662109
- EloralintidePhase 3 · NCT07765511 · NCT07282600 · NCT07589608 · NCT07900633 · NCT07392190 · NCT07321886 · NCT07215559 · NCT07881432
- eloralintide and tirzepatidePhase 3 · NCT07881458 · NCT07881432
- empagliflozinPhase 3 · NCT07093476 · NCT07064473 · NCT04602754 · NCT05028140
- EMPAGLIFLOZIN + LINAGLIPTINPhase 3 · NCT04670666
- EnicepatidePhase 3 · NCT07889648 · NCT07351045 · NCT07351058 · NCT07670416
- Exendin-4 Fc fusion protein injectionPhase 3 · NCT06254014
- Exendin-4 Fc fusion protein injection(1.2mg）Phase 3 · NCT06257966
- Exendin-4 Fc fusion protein injection（2.4mg）Phase 3 · NCT06257966
- Exploratory test groupPhase 3 · NCT07552389
- F027Phase 3 · NCT07046273
- Glimepiride (oral)Phase 3 · NCT07288749
- Group A (triple combination intensive therapy group)Phase 3 · NCT07635953
- Group A (triple combination therapy group)Phase 3 · NCT06946628
- Group B (standard therapy group)Phase 3 · NCT07635953 · NCT06946628
- GZR18Phase 3 · NCT06778967 · NCT06777238 · NCT07055386
- GZR33 InjectionPhase 3 · NCT07527078
- GZR4Phase 3 · NCT06767761 · NCT06767748 · NCT06767735 · NCT07165223
- HDM1002 100 mgPhase 3 · NCT07082114
- HDM1002 200 mgPhase 3 · NCT07193459 · NCT07082114
- HDM1002 400 mgPhase 3 · NCT07193459 · NCT07082114
- HDM1005 1Phase 3 · NCT07109700 · NCT07279194 · NCT07394114 · NCT07417306
- HDM1005 2Phase 3 · NCT07109700 · NCT07279194 · NCT07394114 · NCT07417306
- HDM1005 injection or placeboPhase 3 · NCT07394114
- HM11260CPhase 3 · NCT07379333
- HRS9531Phase 3 · NCT07060456
- HS-20094 InjectionPhase 3 · NCT07156500 · NCT07156539
- HS-20094 Placebo InjectionPhase 3 · NCT07156500
- IN-B00009Phase 3 · NCT07308184
- Inpatient newly diagnosed type 2 diabetes subjectsPhase 3 · NCT06825182
- insulin degludecPhase 3 · NCT07913061 · NCT06767748 · NCT07018453
- Insulin Degludec Injection (Tresiba®)Phase 3 · NCT07527078
- Insulin glarginePhase 3 · NCT06619301 · NCT05098470
- Insulin glargine U-100Phase 3 · NCT07797335
- Insulin Glargine U100Phase 3 · NCT06767735
- Insulin Glargine U100 groupPhase 3 · NCT06767761
- Insulin Icodec groupPhase 3 · NCT07165223
- insulin NPHPhase 3 · NCT06619301 · NCT05124457
- LenbelintidePhase 3 · NCT07784270 · NCT07776509 · NCT07784725
- LID104Phase 3 · NCT05886088
- LinagliptinPhase 3 · NCT05886088
- Liraglutide injectionPhase 3 · NCT06361238
- MADALENA ASSOCIATIONPhase 3 · NCT04670666
- Maridebart cafraglutidePhase 3 · NCT07160257 · NCT07866066 · NCT07871409 · NCT06858839 · NCT06987695 · NCT06660173 · NCT07684144 · NCT06858878
- MazdutidePhase 3 · NCT07083154 · NCT07417306 · NCT07843862
- MetforminPhase 3 · NCT06257966 · NCT07093476 · NCT05345327 · NCT03925714 · NCT06120881 · NCT04670666 · NCT07279909 · NCT05098470
- Metformin HCI XRPhase 3 · NCT06246799
- Nicotine replacementPhase 3 · NCT07059377
- Nigetella salivataPhase 3 · NCT03925714
- NNC0487-0111Phase 3 · NCT07400107 · NCT07533175 · NCT07535307
- Obicetrapib 10 mgPhase 3 · NCT07219602
- obicetrapib 10 mg + ezetimibe 10 mg FDC dailyPhase 3 · NCT07219602
- OrforglipronPhase 3 · NCT06972472 · NCT07613307 · NCT06993792 · NCT07668336 · NCT06972459
- ORMD-0801 16 mgPhase 3 · NCT06731075
- ORMD-0801 8 mgPhase 3 · NCT06731075
- Outpatient newly diagnosed type 2 diabetes subjectsPhase 3 · NCT06825182
- Ozempic®Phase 3 · NCT07046273
- PetrelintidePhase 3 · NCT07843485
- PF-08653944Phase 3 · NCT07400653 · NCT07595549
- PIEMONTEPhase 3 · NCT05028140
- PioglitazonePhase 3 · NCT06246799 · NCT04501406 · NCT05028140
- Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XRPhase 3 · NCT07026968
- Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XRPhase 3 · NCT07026968
- Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XRPhase 3 · NCT07026968
- Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XRPhase 3 · NCT07026968
- Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XRPhase 3 · NCT07026968
- QLG1091Phase 3 · NCT07487103
- RAY1225Phase 3 · NCT07139535 · NCT07139548
- Renal Autologous Cell Therapy (REACT/ rilparencel)Phase 3 · NCT05099770
- RetatrutidePhase 3 · NCT06383390 · NCT06982859 · NCT07232719 · NCT06260722 · NCT06297603 · NCT07357415
- ROSUVASTATIN CALCIUMPhase 3 · NCT04602754
- Rosuvastatin/Dapagliflozin placeboPhase 3 · NCT06772168
- RybelsusPhase 3 · NCT07487103
- SemaglutidePhase 3 · NCT07064486 · NCT07415954 · NCT07866066 · NCT07662213 · NCT03811561 · NCT07855133 · NCT07628985 · NCT07668388 · NCT07187856 · NCT06778967 · NCT07400107 · NCT07428746 · NCT06982859 · NCT07059377 · NCT06260722 · NCT07743983 · NCT07564414 · NCT06005012 · NCT07112872 · NCT07139548 · NCT06717698
- Semaglutide InjectionPhase 3 · NCT07653477
- Semaglutide Pen InjectorPhase 3 · NCT05569772 · NCT05067621
- Semaglutide placeboPhase 3 · NCT05569772 · NCT07668388
- Semaglutide, 1.34 mg/mLPhase 3 · NCT07581145
- Sentagliptin Phosphate - single dosePhase 3 · NCT07241897
- SHR-3167Phase 3 · NCT07913061 · NCT07018453
- SitagliptinPhase 3 · NCT06246799
- Sitagliptin 100mg ODPhase 3 · NCT07073768
- Sleeve gastrectomyPhase 3 · NCT05211375
- SonlicromanolPhase 3 · NCT06451757
- SurvodutidePhase 3 · NCT07754461
- Test groupPhase 3 · NCT07552389
- THP-00101Phase 3 · NCT06647745
- THP-00102Phase 3 · NCT06647745
- THP-00103Phase 3 · NCT06647745
- THP-00104Phase 3 · NCT06647745
- THP-00105Phase 3 · NCT06647745
- THP-00106Phase 3 · NCT06647745
- TirzepatidePhase 3 · NCT05822544 · NCT06700538 · NCT07889648 · NCT07481747 · NCT06246799 · NCT07868354 · NCT06037252 · NCT07881458 · NCT06643728 · NCT07881432 · NCT07299084 · NCT06918405
- Trelagliptin 100 mgPhase 3 · NCT07073768
- tributyrinPhase 3 · NCT07503548
- UBT251 Injection 2.0 mgPhase 3 · NCT07659574
- UBT251 Injection 2.0 mg groupPhase 3 · NCT07653477
- UBT251 Injection 4.0 mgPhase 3 · NCT07659574
- UBT251 Injection 4.0 mg groupPhase 3 · NCT07653477
- UBT251 Injection 6.0 mgPhase 3 · NCT07659574
- UBT251 Injection 6.0 mg groupPhase 3 · NCT07653477
- UBT251 Injection Placebo 2.0 mgPhase 3 · NCT07659574
- UBT251 Injection Placebo 4.0 mgPhase 3 · NCT07659574
- UBT251 Injection Placebo 6.0 mgPhase 3 · NCT07659574
- VicadrostatPhase 3 · NCT07064473
- Vitamin D (Cholecalciferol )Phase 3 · NCT07448974
- VK2735Phase 3 · NCT07868835 · NCT07104500 · NCT07104383
- VK2735 OralPhase 3 · NCT07868939
- VX-017Phase 3 · NCT04786262
- VX-880Phase 3 · NCT04786262
- ZenagamtidePhase 3 · NCT07855133 · NCT07868354 · NCT07797335
- ApabetalonePhase 2/3 · NCT06590324
- AtherolivePhase 2/3 · NCT05605704
- CanagliflozinPhase 2/3 · NCT05427084 · NCT02891954 · NCT05507892
- China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetesPhase 2/3 · NCT07033585
- Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetesPhase 2/3 · NCT07033585
- High-dose LC-Z300-01 twice daily in blindingPhase 2/3 · NCT06847178
- High-dose LCZ300-1 twice daily in open-labelPhase 2/3 · NCT06847178
- Intranasal InsulinPhase 2/3 · NCT07675499
- Intranasal PlaceboPhase 2/3 · NCT07675499
- Low-dose LC-Z300-01 twice daily in blindingPhase 2/3 · NCT06847178
- 1/bag of Jinlida granules, 3 times/day, taken with hot water.Phase 2 · NCT06495814
- 18F-MK6240 injectionPhase 2 · NCT03389100
- Abrocitinib 200 MG Oral TabletPhase 2 · NCT05743244
- Acetazolamide 125 mgPhase 2 · NCT07902726
- Acetazolamide 250 mgPhase 2 · NCT07902726
- Acetazolamide 62.5 mgPhase 2 · NCT07902726
- Active comparator TaurinePhase 2 · NCT04874012
- albumin injectionPhase 2 · NCT06727721
- ALN-4324Phase 2 · NCT06845202 · NCT07465224
- ALN-ANG3Phase 2 · NCT07271186
- Aminohippurate Sodium Inj 20%Phase 2 · NCT03584217 · NCT05507892
- Antithymocyte Globulin (ATG)Phase 2 · NCT07216391
- ApelinPhase 2 · NCT03449251
- ARO-INHBEPhase 2 · NCT06700538 · NCT07859813
- AT673 high dosePhase 2 · NCT07724340
- AT673 low dosePhase 2 · NCT07724340
- BimagrumabPhase 2 · NCT06643728
- Bimagrumab PlaceboPhase 2 · NCT06643728
- CelecoxibPhase 2 · NCT07139405
- ChiglitazarPhase 2 · NCT07303803
- Chiglitazar PlaceboPhase 2 · NCT07303803
- ClazakizumabPhase 2 · NCT07783802
- clofutribenPhase 2 · NCT07296484
- Colchicine 0.5 MG Oral Tablet Once DailyPhase 2 · NCT07837934
- Continuous Insulin InfusionPhase 2 · NCT04542148
- CX11Phase 2 · NCT07340320
- CyclosporinPhase 2 · NCT05153070
- DA-2811Phase 2 · NCT07239440
- DA-2811-CPhase 2 · NCT07239440
- DA-302168SPhase 2 · NCT07877038 · NCT07755150
- Dapagliflozin (Forxiga®)Phase 2 · NCT06072326
- Dapagliflozin 10 MGPhase 2 · NCT07515391 · NCT05938712
- Dapagliflozin 10mgPhase 2 · NCT07902726
- DapansutrilePhase 2 · NCT06047262
- DegludecPhase 2 · NCT07215312
- Dexcom G6 Professional Continuous Glucose MonitorPhase 2 · NCT04542148
- DFMOPhase 2 · NCT05594563
- digital prosthetic interface technologyPhase 2 · NCT05656924
- Digoxin 0.125 MGPhase 2 · NCT06240403
- DT2-SCT intravenous infusionPhase 2 · NCT06789302
- Dulaglutide 1.5 MGPhase 2 · NCT07109700
- Eloralintide PlaceboPhase 2 · NCT07215559
- Empagliflozin 25 MGPhase 2 · NCT05501483 · NCT07053306 · NCT05960656 · NCT07053293 · NCT07053319
- EvinacumabPhase 2 · NCT07271186
- exosomes derived from human umbilical cord mesenchymal stem cellsPhase 2 · NCT07319533
- FORXIGAPhase 2 · NCT07225465
- FulvestrantPhase 2 · NCT07748208
- GL0034 Dose Level 1Phase 2 · NCT07282743
- GL0034 Dose Level 2Phase 2 · NCT07282743
- GL0034 Dose Level 3Phase 2 · NCT07282743
- GL0034 Dose Level 4Phase 2 · NCT07282743
- GL0034 Dose Level 5Phase 2 · NCT07282743
- GL0034 Dose Level 6Phase 2 · NCT07282743
- Guominkang GranulesPhase 2 · NCT07907965
- GZR101-80Phase 2 · NCT07387003
- GZR102Phase 2 · NCT07055386
- GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)Phase 2 · NCT07387003
- HD-6277 100mgPhase 2 · NCT06647550
- HD-6277 25mgPhase 2 · NCT06647550
- HD-6277 50mgPhase 2 · NCT06647550
- HDM1005 3Phase 2 · NCT07109700
- HDM1005 4Phase 2 · NCT07109700
- HM15275Phase 2 · NCT07527650
- HP-211Phase 2 · NCT07546929
- HRS-4729 InjectionPhase 2 · NCT07843862
- HRS9531 TabletPhase 2 · NCT07599410
- HRS9531 Tablet placeboPhase 2 · NCT07599410
- HTD1801Phase 2 · NCT07496177
- Hyperglycemic clampPhase 2 · NCT05499702
- icovamenib 100 mgPhase 2 · NCT07502508
- icovamenib 100mgPhase 2 · NCT07502495
- ILT101Phase 2 · NCT05153070
- InavolisibPhase 2 · NCT07748208
- Insulin DetemirPhase 2 · NCT05124457
- Investigational Product - MIB 626Phase 2 · NCT05759468
- JM-HDPhase 2 · NCT06978023
- JM-LDPhase 2 · NCT06978023
- Kerendia (Finerenone, BAY94-8862)Phase 2 · NCT06906081
- LiraglutidePhase 2 · NCT07029009 · NCT05268237
- Liraglutide Pen InjectorPhase 2 · NCT06976619
- LY3457263Phase 2 · NCT06897475
- LY3938577Phase 2 · NCT07215312
- LY4086940Phase 2 · NCT07890376
- MacupatidePhase 2 · NCT07765511 · NCT07589608 · NCT07215559
- Macupatide PlaceboPhase 2 · NCT07215559
- Magnesium L-lactate dihydratePhase 2 · NCT03567824
- MEI6570Phase 2 · NCT05912218
- MelatoninPhase 2 · NCT07036796
- Mesenchymal stem cellsPhase 2 · NCT06727721
- mesenchymal stem cells with OCN-19Phase 2 · NCT06727721
- Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) TherapyPhase 2 · NCT07144241
- Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) TherapyPhase 2 · NCT07144241
- Metformin XRPhase 2 · NCT07139405
- MKP10241Phase 2 · NCT07098663
- MN-001Phase 2 · NCT05464784
- MN-001 placeboPhase 2 · NCT05464784
- MWN109 1Phase 2 · NCT07801820
- MWN109 2Phase 2 · NCT07801820
- MWN109 3Phase 2 · NCT07801820
- MWN109 4Phase 2 · NCT07801820
- Nano-tocotrienolsPhase 2 · NCT07888426
- NNC0519-0130Phase 2 · NCT06717698
- NNC0662-0419Phase 2 · NCT07415954
- Normal (0.9%) salinePhase 2 · NCT07319533
- Normal salinePhase 2 · NCT03449251
- OPT101Phase 2 · NCT06964087
- oral Semaglutide/RybelsusPhase 2 · NCT06050577
- PalbociclibPhase 2 · NCT07748208
- PG-102Phase 2 · NCT07187856 · NCT06712615
- PG-102(MG12)Phase 2 · NCT07677891
- Pioglitazone 45 mgPhase 2 · NCT05501483
- Platelet Rich PlasmaPhase 2 · NCT06810726
- Polyene Phosphatidyl cholinePhase 2 · NCT07303803
- PS1Phase 2 · NCT07889505
- relacorilantPhase 2 · NCT03604198
- RelaxinPhase 2 · NCT03449251
- RitlecitinibPhase 2 · NCT05743244
- RO7795081Phase 2 · NCT07112872
- SC0062 and dapagliflozinPhase 2 · NCT06072326
- SC0062 strength 10mgPhase 2 · NCT06072326
- Semaglutide 7 MGPhase 2 · NCT05501483
- Semaglutide TabletsPhase 2 · NCT07801820
- Semaglutide, 1.0 mg/mLPhase 2 · NCT05938712
- SGLT-2 inhibitor (Sotagliflozin)Phase 2 · NCT07421518
- SHR-3167 InjectionPhase 2 · NCT07032688 · NCT07472725
- SHR-3167 Injection PlaceboPhase 2 · NCT07472725
- Sliding Scale InsulinPhase 2 · NCT04542148
- SorafenibPhase 2 · NCT06227221
- SotagliflozinPhase 2 · NCT06435156
- Sotagliflozin initiationPhase 2 · NCT07325201
- Standard Antihypertensive, Antidiabetic, and Lipid-Lowering RegimenPhase 2 · NCT07907965
- SYH2069 Injection (group 1)Phase 2 · NCT07796477
- SYH2069 Injection (group 2)Phase 2 · NCT07796477
- SYH2069 Injection (group 3)Phase 2 · NCT07796477
- SYH2069 Injection (group 4)Phase 2 · NCT07796477
- SYH2069 Injection placeboPhase 2 · NCT07796477
- TeplizumabPhase 2 · NCT06791291 · NCT07216391
- Tirzepatide 2.5mg weeklyPhase 2 · NCT06820281
- Tirzepatide Injection 15mgPhase 2 · NCT07796477
- Tirzepatide PlaceboPhase 2 · NCT06643728
- UBT251Phase 2 · NCT07668388
- UBT251 PlaceboPhase 2 · NCT07668388
- Up-Titration of Home InsulinPhase 2 · NCT04542148
- ValsartanPhase 2 · NCT07139405
- VCT220 tabletsPhase 2 · NCT07872436
- vitamin EPhase 2 · NCT07303803
- AdalimumabPhase 1/2 · NCT07061574
- Allogeneic pancreatic endocrine cell clustersPhase 1/2 · NCT07581197
- Anti-thymocyte globulin (ATG)Phase 1/2 · NCT07061574
- Arginine hydrochloridePhase 1/2 · NCT07167693
- ARO-ALK7Phase 1/2 · NCT06937203
- AZD9550Phase 1/2 · NCT06151964
- AZD9550 and AZD6234Phase 1/2 · NCT06151964
- cfMSC therapy for diabetesPhase 1/2 · NCT07495956
- CIL001 (Paliroden)Phase 1/2 · NCT07472907
- Combined prescription of the individual medicationsPhase 1/2 · NCT06143566
- Dendritic cell immunotherapyPhase 1/2 · NCT06866158
- DenosumabPhase 1/2 · NCT06524960
- exosomes treatment groupPhase 1/2 · NCT07693036
- Fish Oil Concentrate, 1000 Mg Oral CapsulePhase 1/2 · NCT05169060
- GUB-UCN2Phase 1/2 · NCT07702890
- Human Pancreatic Islet TransplantationPhase 1/2 · NCT02846571
- Insulin Isophane Human, NPH, Pre-emptive AlgorithmPhase 1/2 · NCT07757464
- Iohexol Inj 300 MG/MLPhase 1/2 · NCT03584217
- PAL-119Phase 1/2 · NCT07901595
- PolypillPhase 1/2 · NCT06143566
- Renal BiopsyPhase 1/2 · NCT03584217
- Salsalate Oral TabletPhase 1/2 · NCT05169060
- Semaglutide (1 Mg Dose)Phase 1/2 · NCT07374328
- SG Depot 2 mgPhase 1/2 · NCT07563699
- SG Depot 4 mgPhase 1/2 · NCT07563699
- SG Depot 6 mgPhase 1/2 · NCT07563699
- SG Depot 8 mgPhase 1/2 · NCT07563699
- Sitagliptin (DPP4 inhibitor)Phase 1/2 · NCT07374328
- Sodium Chloride 0.9%Phase 1/2 · NCT07167693
- Triamcinolone Acetonide Knee InjectionPhase 1/2 · NCT07757464
- verapamil extended-release capsulePhase 1/2 · NCT07061574
- VV-14299Phase 1/2 · NCT07829302
- VV-14300Phase 1/2 · NCT07831798 · NCT07829302
- VX-264Phase 1/2 · NCT05791201
- Ablation TreatmentPhase 1 · NCT05369065
- ACI-19764 at dose A1Phase 1 · NCT07463196
- ACI-19764 at dose A2Phase 1 · NCT07463196
- ACI-19764 at dose A3Phase 1 · NCT07463196
- ACI-19764 at dose A4Phase 1 · NCT07463196
- ACI-19764 at dose A5Phase 1 · NCT07463196
- ACI-19764 at dose A6Phase 1 · NCT07463196
- ACI-19764 at dose B1Phase 1 · NCT07463196
- ACI-19764 at dose B2Phase 1 · NCT07463196
- ACI-19764 at dose B3Phase 1 · NCT07463196
- ACI-19764 at dose C1Phase 1 · NCT07463196
- Administration of UI087Phase 1 · NCT07548957
- Administration of UIC202506, UIC202507, UIC202508Phase 1 · NCT07548957
- Alpelisib 300 mgPhase 1 · NCT07778524
- ALV-100Phase 1 · NCT07399678
- AMG 127Phase 1 · NCT07590193
- Aspirin 162 mg EC Tab once daily for 7 daysPhase 1 · NCT05702463
- Aspirin 40Mg Chew Tab twice daily for 7 daysPhase 1 · NCT05702463
- Aspirin 81Mg Ec Tab twice daily for 7 daysPhase 1 · NCT05702463
- ATB-1011Phase 1 · NCT07590466
- ATB-1012Phase 1 · NCT07590466
- ATB-U101Phase 1 · NCT07590466
- ATB-U1011Phase 1 · NCT07590466
- ATB-U1012Phase 1 · NCT07590466
- AtorvastatinPhase 1 · NCT07534592
- AZD4248Phase 1 · NCT07024823
- Basal insulinPhase 1 · NCT07681375
- Blood Flow RestrictionPhase 1 · NCT07588503
- BLX-7006Phase 1 · NCT07140055
- Chiglitazar/Metformin extended-release tablets after a high-fat mealPhase 1 · NCT07511010
- Chiglitazar/Metformin extended-release tablets under fasting conditionsPhase 1 · NCT07511010
- Degludec IVPhase 1 · NCT06945406
- Degludec SCPhase 1 · NCT06945406
- Dexcom Continuous Glucose Monitoring (CGM)Phase 1 · NCT07681375
- Drug Metabolizing EnzymePhase 1 · NCT05822544
- DWC202502Phase 1 · NCT07539415
- DWC202503Phase 1 · NCT07539415
- DWRX5003Phase 1 · NCT07539415
- Efsubaglutide Alfa InjectionPhase 1 · NCT07518121
- Elecoglipron Reference Formulation Dose APhase 1 · NCT07723833
- Elecoglipron Reference Formulation Dose BPhase 1 · NCT07723833
- Elecoglipron Test formulation 1 Dose APhase 1 · NCT07723833
- Elecoglipron Test formulation 1 Dose BPhase 1 · NCT07723833
- Elecoglipron Test formulation 2 Dose APhase 1 · NCT07723833
- Elecoglipron Test formulation 2 Dose BPhase 1 · NCT07723833
- Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)Phase 1 · NCT07053319
- GL0034Phase 1 · NCT07385547
- GS-4571Phase 1 · NCT06562907
- GZR102 injectionPhase 1 · NCT06974487
- GZR18 injectionPhase 1 · NCT06974487
- GZR18 injection APhase 1 · NCT07355738
- GZR18 injection BPhase 1 · NCT07355738
- GZR4 injectionPhase 1 · NCT07146347 · NCT06974487
- GZR4 injection APhase 1 · NCT07670897
- GZR4 injection BPhase 1 · NCT07670897
- HMS1005Phase 1 · NCT07568678
- HRS-1596Phase 1 · NCT07841860
- HRS-1596 PlaceboPhase 1 · NCT07841860
- HRS-4729Phase 1 · NCT07807059
- HRS9531 tabletsPhase 1 · NCT06506175
- Insulin Degludec InjectionPhase 1 · NCT07032688 · NCT07630233
- Insulin Icodec InjectionPhase 1 · NCT07630233
- Lispro SCPhase 1 · NCT06945406
- LY4057996 IVPhase 1 · NCT06945406
- LY4057996 SCPhase 1 · NCT06945406
- LY4167586Phase 1 · NCT07881887
- Matching placeboPhase 1 · NCT07568678
- MS-553Phase 1 · NCT04187443
- multiple-dose of Chiglitazar/Metformin extended-release tabletsPhase 1 · NCT07511010
- MWN105 1Phase 1 · NCT07803809
- MWN105 2Phase 1 · NCT07803809
- MWN105 3Phase 1 · NCT07803809
- Neurotronic Infusion CatheterPhase 1 · NCT05363761
- NNC1679-0001Phase 1 · NCT07570992
- NNC9733-0001Phase 1 · NCT07270731
- NNC9836-0001Phase 1 · NCT07896109
- OmeprazolePhase 1 · NCT06562907
- Only PRP injectionPhase 1 · NCT05610865
- ONO-3310Phase 1 · NCT07619157
- PATAS TrifluoroacetatePhase 1 · NCT07223333
- Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin PlaceboPhase 1 · NCT07053319
- Pre-study basal insulin SCPhase 1 · NCT06945406
- PRP + ASCs injectionPhase 1 · NCT05610865
- PRP + SVF injectionPhase 1 · NCT05610865
- QX1206Phase 1 · NCT06694935
- REGEND003Phase 1 · NCT07275788
- RGB-5088Phase 1 · NCT07794254
- RO7204239Phase 1 · NCT07137585
- RosuvastatinPhase 1 · NCT07534592
- RZ-629Phase 1 · NCT06829563
- Semaglutide Pen Injector [Ozempic]Phase 1 · NCT05071898
- Single Arm non-Randomized Ablation TreatmentPhase 1 · NCT05369065
- THCPhase 1 · NCT05322213
- TLC-6740 Oral SolutionPhase 1 · NCT05822544
- TLC-6740 TabletPhase 1 · NCT05822544
- TQF3250 capsulesPhase 1 · NCT07747857
- TQF3250 placeboPhase 1 · NCT07747857
- Treatment A(AD-236A)Phase 1 · NCT07730567
- Treatment B(AD-236B)Phase 1 · NCT07730567
- Treatment C(AD-236A+AD-236B)Phase 1 · NCT07730567
- UBT38006Phase 1 · NCT07630233
- ZE63-0302Phase 1 · NCT07234864
- Addition of Hengge Liejing treatment for 48 weeksEarly phase 1 · NCT07198516
- Adjustment of insulin doses CFTEarly phase 1 · NCT06826547
- Adjustment of insulin doses DAREarly phase 1 · NCT06826547
- Aspirin 80 mg EC TabEarly phase 1 · NCT05105919
- Autologous islet transplantationEarly phase 1 · NCT07118475
- C13 Hyperpolarized pyruvate injectionEarly phase 1 · NCT07820722
- DPP System (Insulin Pump and Continuous Glucose Monitoring Platform)Early phase 1 · NCT07655076
- Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））Early phase 1 · NCT07347080
- Glucagon-Like Peptide- 1 (GLP-1) infusionEarly phase 1 · NCT01858896
- Ketone Monoester (KE)Early phase 1 · NCT06108076
- local antibiotic application of topical minocyclineEarly phase 1 · NCT07298057
- MontelukastEarly phase 1 · NCT07409714
- Montelukast PlaceboEarly phase 1 · NCT07409714
- Phentermine/Topiramate (Qsymia)Early phase 1 · NCT04881799
- Sanggua tabletsEarly phase 1 · NCT06964620
- Scaling and Root PlaningEarly phase 1 · NCT07298057
- Semaglutide (Rybelsus®)Early phase 1 · NCT06338553
- Sodium Glucose Co-transporter 2 (SGLT2) InhibitorEarly phase 1 · NCT06609356
- Standard Oral Hypoglycemic AgentEarly phase 1 · NCT07209527
- Study Visit 1Early phase 1 · NCT06609356
- Study Visit 2Early phase 1 · NCT06609356
- TrehaloseEarly phase 1 · NCT05593549
- Truway Blood Glucose MonitorEarly phase 1 · NCT07209527
- Truway Portable Ultrasound DeviceEarly phase 1 · NCT07209527
Closest to patients
- Safety and Efficacy of AT-001 in Patients With Diabetic CardiomyopathySafety and Efficacy of AT-001 in Patients With Diabetic CardiomyopathyNew Generation of Medical Research · Hialeah, United States + 78 more hospitalsPhase 3Primary completion 2023
- Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase ActivityEffects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase ActivityRita Basu · Birmingham, United States + 1 more hospitalPhase 3Primary completion 2025
- Current Status of Islet Alpha Cell Function in Patients with Type 2 DiabetesCurrent Status of Islet Alpha Cell Function in Patients with Type 2 DiabetesNanjing First Hostital · Nanjing, ChinaPhase 3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Anthropometric, Muscle Function, Physical Activity, Inflammatory and Dietary Characteristics Associated With Fasting Glucose and Insulin Resistance in Rural and Urban Malawian Adults: A Cross-Sectional Study.
Anthropometric, Muscle Function, Physical Activity, Inflammatory and Dietary Characteristics Associated With Fasting Glucose and Insulin Resistance in Rural and Urban Malawian Adults: A Cross-Sectional Study.
Diabetes, obesity & metabolism
PubMed · PMID 42977538Publication
Effect of metformin use in patients with type 2 diabetes mellitus on the risk of a first acute pancreatitis event, severe acute pancreatitis and progression to chronic pancreatitis: a cohort discovery study.
Effect of metformin use in patients with type 2 diabetes mellitus on the risk of a first acute pancreatitis event, severe acute pancreatitis and progression to chronic pancreatitis: a cohort discovery study.
BMJ open gastroenterology
PubMed · PMID 42977330Publication
Effects of Vitamin D 3 Supplementation on Glycaemic Parameters and Insulin Sensitivity in Pre-diabetic Adults: A Prospective Controlled Interventional Study.
Effects of Vitamin D 3 Supplementation on Glycaemic Parameters and Insulin Sensitivity in Pre-diabetic Adults: A Prospective Controlled Interventional Study.
The Nigerian postgraduate medical journal
PubMed · PMID 42975227Publication
Efficacy and Safety of Dapagliflozin, Glimepiride, and Metformin Fixed-Dose Combination Tablet in Type 2 Diabetes: A Phase III Trial.
Efficacy and Safety of Dapagliflozin, Glimepiride, and Metformin Fixed-Dose Combination Tablet in Type 2 Diabetes: A Phase III Trial.
Advances in therapy
PubMed · PMID 42970163
Find fellow researchers
Groups with active Type 2 diabetes work.
University of Copenhagen
Copenhagen, Denmark
Team details appear once the team leader joins.
Is this your team? Claim it
Brigham and Women's Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Karolinska Institutet
Stockholm, Sweden
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Imperial College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
University of Michigan
Ann Arbor, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Fudan University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it